Literature DB >> 7208337

[Pharmacokinetics of fenofibrate in man (author's transl)].

C Harvengt, J P Desager.   

Abstract

The active metabolite of fenofibrate is fenofibric acid, which is strongly bound to serum proteins. Following a single oral dose of 300 mg fenofibrate there is a diphasic decrease in plasma levels of fenofibric acid, and most of the drug is excreted as conjugate in the urine. Following daily oral administration of 300 mg during 10 days, a state of equilibrium is obtained within 2 to 3 days and persists throughout the observation period; the mean elimination half-life and urinary excretion rate are very similar to those measured after a single dose, and the drug does not accumulate. In patients with renal insufficiency, the plasma half-life of fenofibric acid is very substantially prolonged and considerable accumulation takes place, as the compound is virtually not dialyzable. Doses of 100 mg/day produce plasma levels similar to those obtained with 300 mg/day. The lipid-lowering activity mostly affects triglycerides. Concomitant administration of colestipol has no effect on blood kinetics and urinary excretion of fenofibrate but results in very important reduction of all lipoprotein fractions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7208337

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  2 in total

1.  Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

Authors:  Lauri I Kajosaari; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status.

Authors:  Agnieszka Makówka; Przemysław Dryja; Grażyna Chwatko; Edward Bald; Michał Nowicki
Journal:  Lipids Health Dis       Date:  2012-07-06       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.